Drugs / RXRG001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06714253 | Mar 2025 → Aug 2027 expected | — | RiboX Therapeutics Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RXRG001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06714253 ↗ |
| Modality | Other / unclassified | “Circular ribonucleic acid encoding human aquaporin 1 encapsulated in a lipid nanoparticle” NCT06714253 ↗ |
| Route | Other | “RXRG001 administered intraductally in the salivary gland (unilateral)” NCT06714253 ↗ |